LA JOLLA, Calif.--(BUSINESS WIRE)--Immunosyn Corporation (OTCBB:IMYN), a biotechnology firm that has obtained exclusive worldwide marketing, sales and distribution rights to the biopharmaceutical SF-1019 from its affiliate Argyll Biotechnologies, LLC, has announced its results for the quarter ending September 30, 2008.
